DNCS (Drug-Navigated Clearance System)

Some cytokines and inflammatory mediators are considered to be pathogeneses of rheumatoid arthritis (RA), which are referred to as rheumatoid factors (RF). We have developed a novel therapeutic strategy, drug-navigated clearance system (DNCS), which leads the autoantibody, RF, toward the hepatic LDL receptors (LDLRs) by use of a newly designed drugs, "navigator". Protein A that bind to the target antibody (RF) was chemically conjugated to apolipoprotein E (ApoE) which directly bind to the hepatic LDLR and dextran sulfate (DexS) which binds to LDL and then indirectly accumulate to the liver. The conjugation reaction was monitored on SDS-PAGE. In vitro uptake of fluorescently labeled IgG by HepG2 was greatly increased in the presence of navigator molecule. In addition, the elevated RF level of the RA model rat was reduced immediately after the navigator injection and last for about 2 days.

Publications

1. US8,834,887 B2.

last updated：2021/10/01